// App-Quantinova.ai

118 : Baricitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: 52 Week Safety and Efficacy in an Open-Label, Long-Term Extension Study

Researchers

Presenter

  • Youb Chalabi

Principal Investigators

  • Mark Genovese

  • Peter Taylor

  • Douglas Schlichting

  • Scott Beattie

  • William Macias

  • Edward Keystone

Medical Centers

  • University of Victoria, Victoria, BC, Canada

  • Mount Sinai Hospital, Toronto, ON, Canada

  • Montreal, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

Biomarkers

  • N/A

Drug/Treatment

  • Baricitinib

Outcome

  • Unknown

Study Design

  • open label

  • randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved